SPOTLIGHT: Analysts ponder Cervarix delay

There's been a considerable number of post mortems on the FDA's decision to delay a decision on GlaxoSmithKlines's Cervarix, a cervical cancer vaccine that is already approved in Europe and has the capacity to become a blockbuster therapy in competition with Merck's Gardasil. Motley Fool's Brian Lawler is betting that the European Medicine Agency's green light indicates only a small hold-up for Cervarix. Glaxo added considerably to the uncertainty around the delay when it declined to spell out exactly what the regulators want to know. In the meantime, though, Gardasil has gained even more time to establish itself as the leader in the HPV vaccine race. Article

Suggested Articles

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.